Prescription drug · NDA
Cytomel (Liothyronine sodium) NDC 60793-117
Liothyronine sodium 50 ug/1 · Tablet · Oral · Pfizer Laboratories Div Pfizer Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 60793-117-01 | 60793011701 | 100 TABLET in 1 BOTTLE (60793-117-01)Marketed from May 8, 1956 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cytomel
- Generic name (nonproprietary)
- liothyronine sodium
- Active ingredients
- Liothyronine sodium — 50 ug/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Pfizer Laboratories Div Pfizer IncNDC labeler code 60793
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 010379
- Marketing start
- Listing expires
- Other FDA classes
- Triiodothyronine (Chemical structure)
- Identifiers
- Product ID 60793-117_5c1150d8-903d-4c39-aa66-5a095ee1b00aSPL ID 5c1150d8-903d-4c39-aa66-5a095ee1b00aSPL set ID 51452b31-ff68-4e0c-b982-c15502ebf1d3RxCUI 903456, 903458, 903697, 903699, 903703, 903705UNII GCA9VV7D2N
- Pharmacologic class
- l-Triiodothyronine
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N460793011701followed by a unit qualifier and the quantityPackage 60793-0117-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
CYTOMEL is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) • Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) • Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 ) Limitations of Use : - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. ( 1 ) - Not indicated for trea…
Excerpt only. Read the full label for complete information.
About NDC 60793-117
- What is NDC 60793-117?
- 60793-117 is the product NDC for Cytomel (liothyronine sodium), Liothyronine sodium 50 ug/1 tablet, listed with the FDA by Pfizer Laboratories Div Pfizer Inc. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Cytomel (Liothyronine sodium).
- What is the active ingredient?
- Liothyronine sodium.
- Who is the labeler?
- Pfizer Laboratories Div Pfizer Inc, NDC labeler code 60793. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Cytomel?
- 2 other product NDCs are listed under this name. See all Cytomel NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Cytomel products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Cytomelliothyronine sodium | Liothyronine sodium 5 ug/1 | TabletOral | Pfizer Laboratories Div Pfizer Inc | 60793-115 | 60793-0115-01 |
| Cytomelliothyronine sodium | Liothyronine sodium 25 ug/1 | TabletOral | Pfizer Laboratories Div Pfizer Inc | 60793-116 | 60793-0116-01 |
Other NDCs under NDA 010379
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Cytomelliothyronine sodium | Liothyronine sodium 5 ug/1 | TabletOral | Pfizer Laboratories Div Pfizer Inc | 60793-115 |
| Cytomelliothyronine sodium | Liothyronine sodium 25 ug/1 | TabletOral | Pfizer Laboratories Div Pfizer Inc | 60793-116 |
| Liothyronine Sodium | Liothyronine sodium 5 ug/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-1206 |
| Liothyronine Sodium | Liothyronine sodium 25 ug/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-1207 |
| Liothyronine Sodium | Liothyronine sodium 50 ug/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-1208 |